News

ATCC Hires New Chief Commercial Officer

ATCC, the world’s premier biological materials management and standards organization, today announced it has hired Greg Ballish as its new Chief Commercial Officer. In his role, Ballish will head ATCC’s sales and marketing operations and partner with Ruth Cheng, Ph.D., Chief Innovation and Strategy Officer and Vice President of Corporate Development of ATCC, to oversee the corporate business and commercial center. As part of the executive leadership team, Ballish will focus on growing the company’s global footprint and reinforcing ATCC’s position as the de facto leader in biological resources.

“We are fortunate to add Greg’s considerable experience and inclusive management style to our executive team, and we look forward to seeing the impact of his commercial leadership,” said Raymond H. Cypess, DVM, Ph.D., Chairman and CEO of ATCC. “In his role, Greg will ensure that we remain a customer-centric organization and continue our commitment to exceeding expectations and fostering long-lasting partnerships with the institutions and organizations we serve.”

Ballish brings an extensive sales, marketing and operations background in the diagnostics, pharmaceuticals, medical devices, transfusion medicine and medical distribution markets to ATCC. He has guided organizations to top market share positions and held key leadership sales and marketing roles for companies including Abbott Labs, DuPont, Johnson & Johnson, LabCorp, LGC Clinical Diagnostics, Meridian Bioscience, Terumo BCT and the American Red Cross. Ballish holds a Master of Business Administration from Arizona State University and a Bachelor of Science in finance from Miami University.

Recent News

11/08/2024

Catalyzing Crucial Cross-Border Collaborations and Innovation to Address Unmet Needs in Rare Diseases

The World Health Organization (WHO) defines a rare disease (RD), or orphan disease, as affecting fewer than 65 per 100,000 people. Although individual RDs are uncommon, collectively, over 10,000 rare diseases impact about 400 million people globally—roughly 5% of the world’s population. Almost 95% of these diseases remain without a single approved treatment. Orphan drugs

11/05/2024

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Adial Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company’s Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical,

10/29/2024

Kaléo Announces Chief Development Officer

Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today announced the appointment of Theresa Matkovits, Ph.D., as its new Chief Development Officer. Dr. Matkovits brings a wealth of experience as a transformational C-suite business leader with a strong track record of driving global drug development and commercialization efforts. With